Acrivon Therapeutics (ACRV) Return on Capital Employed (2022 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Return on Capital Employed of 76.45% for Q1 2026, down 2256.0% year-over-year from 3.55% in Q1 2025, and down 10.74% quarter-over-quarter from 69.03% in Q4 2025.
Acrivon Therapeutics (ACRV) Return on Capital Employed (2022 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Return on Capital Employed for 5 consecutive years, with 76.45% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2256.0% year-over-year to 76.45%; the TTM figure through Mar 2026 stood at 76.45% (down 2256.0% YoY), while the FY2025 annual figure was 57.03%, up 235.0% from the prior year.
- Return on Capital Employed eased to 76.45% in Q1 2026 per ACRV's latest filing, from 69.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.43% in Q1 2023 and bottomed at 76.45% in Q1 2026.
- Historically, Return on Capital Employed has averaged 49.18% across 5 years, with a median of 49.21% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 3505 bps — and 2025, when it jumped 458 bps.
- Acrivon Therapeutics' Return on Capital Employed stood at 25.52% in 2022, then plunged by 100 bps to 51.08% in 2023, then grew by 7 bps to 47.34% in 2024, then plunged by 46 bps to 69.03% in 2025, then decreased by 11 bps to 76.45% in 2026.
- Business Quant data shows ACRV's Return on Capital Employed at 76.45% in Q1 2026, 69.03% in Q4 2025, and 64.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | -85.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.17% |
| Mar 31, 2026 | -76.45% |
| Dec 31, 2025 | -69.03% |
| Sep 30, 2025 | -64.90% |
| Jun 30, 2025 | -61.29% |
| Mar 31, 2025 | -53.89% |
| Dec 31, 2024 | -47.34% |
| Sep 30, 2024 | -41.05% |
| Jun 30, 2024 | -46.45% |
| Mar 31, 2024 | -58.48% |
| Dec 31, 2023 | -51.08% |
| Sep 30, 2023 | -38.28% |
| Jun 30, 2023 | -31.27% |
| Mar 31, 2023 | -23.43% |
| Dec 31, 2022 | -25.52% |